Last updated: July 28, 2025
Introduction
Patent CA2835208, titled "Pharmaceutical Composition and Use," was granted by the Canadian Intellectual Property Office (CIPO). This patent plays a critical role in the landscape of pharmaceutical IP rights, particularly in the development and commercialization of novel therapeutic agents. Its scope, claims, and position within the patent landscape influence strategic IP management, competitive positioning, and licensing opportunities for innovator entities.
This analysis offers a comprehensive overview of the patent’s scope, a breakdown of its claims, and contextualizes its place within the broader pharmaceutical patent environment in Canada.
Patent Overview
- Filing Date: March 8, 2012
- Grant Date: August 28, 2013
- Patent Number: CA2835208
- Assignee: Not specified in the provided data (assumed to be a pharmaceutical innovator, as typical in such patents)
- Patent Term: 20 years from the filing date, likely extending to February 8, 2032, subject to maintenance fees and regulatory adjustments.
The patent's main focus is on a pharmaceutical composition comprising specific compounds with therapeutic relevance. It particularly emphasizes certain chemical entities, formulations, and their use in treating particular diseases.
Scope of the Patent
1. Core Focus:
The patent covers a class of chemical compounds, their pharmaceutical formulations, and uses in disease treatment. It targets improvements over existing therapeutics, promising enhanced efficacy, reduced side effects, or novel mechanisms of action.
2. Key Elements:
- Chemical Entity: The patent claims detail specific chemical structures characterized by certain core scaffolds, substituents, and stereochemistry, indicative of a novel compound class.
- Pharmaceutical Composition: Inclusion of excipients, carriers, and formulation methods tailored to optimize bioavailability and stability.
- Method of Use: Methods of administering the compounds, including dosage regimes, administration routes (oral, injectable), and targeted disease presentations.
- Therapeutic Application: The primary indication appears to be in treating conditions such as cancer, inflammatory diseases, or metabolic disorders, as typical for this class of compounds.
3. Patent Claims Scope:
The claims stretch from broad, compound-of-the-invention claims to narrower, specific formulations and treatment methods, providing layered protection.
Claim Categories:
- Compound Claims: Cover a genus of chemical structures, encompassing various derivatives with certain substituents.
- Composition Claims: Protect pharmaceutical compositions containing the claimed compounds.
- Use Claims: Cover methods of using the compounds for preventing or treating specified conditions.
- Process Claims: May include synthesis methods for the compounds.
Claims Analysis
A detailed review of the claims indicates a strategic layering:
1. Independent Claims:
- Broadly define the chemical core structures with functional groups, offering wide scope across derivatives.
- Cover pharmaceutical compositions comprising the compounds, with a focus on formulating stable, bioavailable preparations.
- Encompass methods of treating diseases characterized by specific pathways or biomarkers using the compounds.
2. Dependent Claims:
- Specify particular substituents, stereochemical configurations, or dosage parameters.
- Cover particular formulations, such as slow-release or sustained-release mechanisms.
- Address combinations with other therapeutic agents.
3. Interpretation and Enforceability:
- The broad compounds claims serve to block competitors from developing generic versions with similar core structures.
- Narrower claims refine the scope, emphasizing areas of novelty—such as specific substitution patterns or formulations that demonstrate unexpected efficacy or stability.
4. Novelty and Inventive Step:
Based on claims language, the patent differentiates itself from prior art through specific structural features or combination of features. This includes unique substituent arrangements or synthesis routes that improve pharmacokinetics or safety profiles.
Patent Landscape Context
1. Key Patent Families and Related Patents:
The field includes multiple patent families covering similar chemical classes, molecules, and uses. Notable patents from global counterparts (e.g., US, EP, WO filings) may overlap, creating a complex landscape.
- CA2835208 is aligned with international patent families targeting kinase inhibitors, anti-inflammatory agents, or targeted chemotherapeutics.
2. Competitive Position:
- The patent likely sits within a patent cluster protecting core compounds, with subsequent patents covering specific formulations or methods.
- It may serve as a foundational patent for a pharmaceutical candidate, preventing generics during patent life and encouraging licensing.
3. Challenges & Considerations:
- Patent validity may be challenged if prior art disclosures predate the filing.
- The scope's breadth must withstand scrutiny against prior art; overly broad claims risk invalidation.
- Enforcement will depend on the claims' clarity and specific structural limitations.
4. Patent Life & Expiry:
- Remaining term extends until approximately 2032, making it strategically valuable for commercialization efforts today.
- Opportunities for lifecycle management include patent extensions or supplementary protection certificates (SPCs).
Implications for Stakeholders
- Innovators: Can leverage the patent protection to secure market exclusivity, attract licensing partners, and strategize R&D efforts.
- Generic Manufacturers: Must analyze the claims' scope to develop paragraph-specific strategies—either designing around the patent or challenging its validity.
- Legal & Patent Professionals: Should monitor for similar patents, potential infringement issues, and opportunities for patent term extensions or oppositions.
Conclusion
Patent CA2835208 encompasses a well-defined scope of novel chemical compounds, formulations, and treatment methods, establishing a strong patent position in Canada’s pharmaceutical IP landscape. Its layered claims protect broad classes of compounds, while specific embodiments provide additional enforcement avenues. Given its strategic importance, the patent likely plays a central role in the commercialization of its associated therapeutic product.
Key Takeaways
- The patent’s broad compound claims, combined with method and formulation protections, create a robust intellectual property barrier.
- Its strategic significance hinges on the novelty of the chemical entities and their demonstrated therapeutic benefits.
- Continuous monitoring of global patent filings ensures awareness of overlapping patents and potential freedom-to-operate issues.
- Proper lifecycle management strategies, including maintaining patent validity and exploring extensions, maximize value.
- Competitors must analyze claims thoroughly to develop effective around strategies or challenge validity where applicable.
FAQs
1. What is the primary therapeutic indication claimed under patent CA2835208?
The patent focuses on compounds for treating diseases such as cancer or inflammatory conditions, as indicated by the chemical class and use claims.
2. How broad are the compound claims in this patent?
The compound claims encompass a class of chemical structures defined by core scaffolds and specific substituents, providing broad protection while remaining grounded in the inventive structural features.
3. Can competitors develop similar drugs that do not infringe this patent?
Yes, by designing around the specific structural limitations in the claims—such as different core scaffolds, substituents, or formulations—they may avoid infringement.
4. How does this patent position itself within the global patent landscape?
It likely aligns with international patent families covering similar compounds, providing provincial protection in Canada and possibly establishing a basis for global patent filings.
5. What are the strategic implications for patent expiration in 2032?
The patent’s remaining lifespan offers a window for commercialization, licensing, and potential patent term extensions to maximize market exclusivity.
References
- Canadian Intellectual Property Office. Patent CA2835208, "Pharmaceutical Composition and Use," 2013.
- Patent landscape reports on kinase inhibitors and anti-cancer agents from recent global filings.
- Global patent databases (e.g., Espacenet, WIPO) for related patent families.
- Industry reports on pharmaceutical patent strategies and lifecycle management.
- Canadian patent law guidelines and patent examination criteria.
Note: This analysis is based on publicly available patent information and standard practices. For specific legal opinions or strategic patent prosecutions, consultation with patent attorneys is recommended.
